Recombinant Immunoglobulin Forms--Cancer Therapy /Diagn.

重组免疫球蛋白形式——癌症治疗/诊断。

• 批准号: 6559282
• 负责人: JEFFREY SCHLOM
• 金额: --
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6559282
• 关键词: CD antigens; antigen antibody reaction; antineoplastics; biotechnology; clinical trials; drug design /synthesis /production; human subject; human therapy evaluation; immunoglobulins; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; patient oriented research; pharmacokinetics; recombinant proteins; tumor antigens

The overall goal of ongoing research is the design and characterization of recombinant immunoglobulin (Ig) forms for use in both therapeutic and diagnostic applications for a range of human cancers. Emphasis is being placed on the design and translational research of humanized CDR-grafted and CDR-modified Ig forms, domain-deleted Ig forms and single-chain fusion molecules. These studies are being conducted using a monoclonal antibody (MAb) of potential clinical utility designated CC49. This MAb has been shown to target a wide range of human tumors clinically and has demonstrated anti-tumor activity in clinical trials as a murine Ig. Studies are ongoing to identify those CDRs that are essential for antigen binding and those that may be immunogenic in humans to better define those variants that are of potential clinical utility.

正在进行的研究的总体目标是设计和表征重组免疫球蛋白（Ig）形式，用于一系列人类癌症的治疗和诊断应用。重点是人源化CDR移植和CDR修饰Ig形式、结构域缺失Ig形式和单链融合分子的设计和转化研究。这些研究正在使用一种具有潜在临床用途的单克隆抗体 (MAb) 进行，该单克隆抗体被命名为 CC49。这种单克隆抗体在临床上已被证明可以靶向多种人类肿瘤，并且在临床试验中显示出作为小鼠 Ig 的抗肿瘤活性。正在进行研究以确定对于抗原结合至关重要的 CDR 以及可能对人类具有免疫原性的 CDR，以更好地定义那些具有潜在临床用途的变体。